Traws Pharma Inc (TRAW) Stock Price, Quote & News

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3680

Fax: 267 759 3681

Website: www.trawspharma.com

Address:

12 Penns Trail, Newtown, United States

StockScanners Nov. 15 at 4:02 AM

$TRAW keep watch if this holds above 2

0 · Reply

Twitties00 Nov. 14 at 11:29 PM

$TRAW 🇺🇸💎🔥Going to be a MONSTER!⏳⏱️🛸

0 · Reply

ShortSecurities Nov. 14 at 8:21 PM

$TRAW Spaghetti legs

0 · Reply

Twitties00 Nov. 14 at 8:02 PM

$TRAW can anyone tell me the estimated annual market for a best in class flu antiviral and a best in class Covid antiviral? 🇺🇸💎🔥

0 · Reply

topstockalerts Nov. 14 at 8:00 PM

Top Gainers PT2 $IVVD $TRAW $TOI $PGEN $WTO

0 · Reply

Shortski Nov. 14 at 7:57 PM

$TRAW Under 2 end of day

0 · Reply

Maryam2000 Nov. 14 at 7:49 PM

$TRAW mother fuckers

0 · Reply

PaulLaurent Nov. 14 at 7:38 PM

📊🔥 Top Gainers Update 💰🚨RTH 2:34pm $CYPH $CYCU $BCG $IVVD $TRAW

0 · Reply

Dwarn2021 Nov. 14 at 7:29 PM

$TRAW So - there was a human case of bird flu in WA State reported today. Also Cidara just inked a deal to be bought by Merck for 9 Billion. Cidara has a non vaccine flu theraputic. For those wondering whats going on with 7M volume. lot of upside from here. I own 3.5% of the shares outstanding.

1 · Reply

topstockalerts Nov. 14 at 7:19 PM

$TRAW setting up nicely.. 🍾

0 · Reply

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 22, 2025, 6:40 PM EDT - 23 days ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 3 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 14, 2025, 1:14 PM EDT - 3 months ago

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 3 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 8, 2025, 7:00 AM EDT - 3 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Jun 30, 2025, 6:30 AM EDT - 4 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

May 27, 2025, 8:00 AM EDT - 6 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 15, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Apr 1, 2025, 8:50 PM EDT - 8 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Mar 28, 2025, 4:30 PM EDT - 8 months ago

Traws Pharma Announces Management Updates

Mar 26, 2025, 7:30 AM EDT - 8 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 25, 2025, 7:30 AM EDT - 8 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 8 months ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 3, 2025, 7:00 AM EST - 9 months ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Feb 28, 2025, 7:00 AM EST - 9 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Jan 23, 2025, 7:00 AM EST - 10 months ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 10, 2025, 5:55 PM EST - 11 months ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Dec 30, 2024, 8:00 AM EST - 11 months ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 23, 2024, 12:00 PM EST - 11 months ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 7:00 AM EST - 11 months ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants

Mar 8, 2024, 8:00 AM EST - 1 year ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 14, 2023, 8:18 PM EST - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 7, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 4, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

StockScanners Nov. 15 at 4:02 AM

$TRAW keep watch if this holds above 2

0 · Reply

Twitties00 Nov. 14 at 11:29 PM

$TRAW 🇺🇸💎🔥Going to be a MONSTER!⏳⏱️🛸

0 · Reply

ShortSecurities Nov. 14 at 8:21 PM

$TRAW Spaghetti legs

0 · Reply

Twitties00 Nov. 14 at 8:02 PM

$TRAW can anyone tell me the estimated annual market for a best in class flu antiviral and a best in class Covid antiviral? 🇺🇸💎🔥

0 · Reply

topstockalerts Nov. 14 at 8:00 PM

Top Gainers PT2 $IVVD $TRAW $TOI $PGEN $WTO

0 · Reply

Shortski Nov. 14 at 7:57 PM

$TRAW Under 2 end of day

0 · Reply

Maryam2000 Nov. 14 at 7:49 PM

$TRAW mother fuckers

0 · Reply

PaulLaurent Nov. 14 at 7:38 PM

📊🔥 Top Gainers Update 💰🚨RTH 2:34pm $CYPH $CYCU $BCG $IVVD $TRAW

0 · Reply

Dwarn2021 Nov. 14 at 7:29 PM

1 · Reply

topstockalerts Nov. 14 at 7:19 PM

$TRAW setting up nicely.. 🍾

0 · Reply

ItTakesItAll Nov. 14 at 7:02 PM

$TRAW 110%+ 1.53-3.28(10/09) and today up again🎈

0 · Reply

dln101 Nov. 14 at 7:02 PM

$YDKG how about a post split bounce to $TRAW levels first 🤔💪📈 $CYPH style

1 · Reply

Twitties00 Nov. 14 at 6:48 PM

$TRAW can anyone tell me the estimated annual market for a best in class flu antiviral and a best in class Covid antiviral? 🇺🇸💎🔥

0 · Reply

Peaceouty Nov. 14 at 6:34 PM

$TRAW discord pump most likely

0 · Reply

Jbjb90 Nov. 14 at 6:26 PM

$TRAW whatd i miss? earnings yesterday and then 7 mil volume today, just a delayed reaction from the market?

1 · Reply

topstockalerts Nov. 14 at 6:15 PM

Top Gainers PT2 $CYCU $TRAW $SMTK $PGEN $TOI

1 · Reply

topstockalerts Nov. 14 at 5:40 PM

$TRAW primed for continuation.. ✅📈 Stay tuned bulls!!

0 · Reply

Corpser1839 Nov. 14 at 5:35 PM

$TRAW

1 · Reply

lecorb Nov. 14 at 5:34 PM

$CYPH $IVVD $CDTX $TRAW

0 · Reply

JamesOliverTrades Nov. 14 at 5:24 PM

📈 $TRAW – Long setup identified. See chart for the entry and Target 1. Hope this helps! #TradeIdeas #StocksToBuy #TechnicalAnalysis #ThinkOrSwim #Investing #TrawsPharma

0 · Reply

MWM Nov. 14 at 5:16 PM

$TRAW added some shares here with this micro share structure. If good news comes this could be $100.

1 · Reply

Maryam2000 Nov. 14 at 5:12 PM

$TRAW 4/5/6

0 · Reply

Market Cap	12.61M
Revenue (ttm)	230,000.00
Net Income (ttm)	-166.52M
EPS (ttm)	N/A
PE Ratio	0.02
Forward PE	N/A
Profit Margin	-72,400.00%
Debt to Equity Ratio	0.00

Volume	8,117,200
Avg Vol	341,884
Day's Range	N/A - N/A
Shares Out	7.13M
Stochastic %K	41%
Beta	1.73
Analysts	Strong Buy
Price Target	$6.00